Critical limb ischemia (CLI) is a manifestation of peripheral arterial disease (PAD) that describes patients with chronic ischemic rest pain or with ischemic skin lesions, either ulcers, or gangrene. CLI is associated with an extremely poor prognosis for both survival and limb salvage; amputation-free survival after 1 year is as low as 50%, and most of the patients ultimately need a revascularization procedure ([@B1]).

Recent studies have confirmed the effectiveness of revascularization with percutaneous transluminal angioplasty (PTA) for patients with CLI; its outcomes seem similar to surgical revascularization even in infrapopliteal segments ([@B2],[@B3]). Because of its minimal invasiveness, PTA is ideally suited even to those at high risk for bypass surgery, including patients with diabetes. The increasingly wide application of PTA now calls for established preoperative risk assessment.

It is well known that CLI has a high prevalence of diabetes. The presence of diabetes in the general population and poor glycemic control in diabetic patients are associated with infection and delayed wound healing as well as micro- and macroangiopathy ([@B4][@B5][@B6][@B7]--[@B8]). Therefore, we thought that glycemic control may influence the prognosis of CLI patients.

Few studies have, however, examined the association of preoperative factors, including diabetic condition, with mortality and limb loss in CLI patients, especially those undergoing PTA ([@B9]). The aim of this study was to reveal the influence of a variety of preoperative factors including diabetic condition on their outcome.

RESEARCH DESIGN AND METHODS
===========================

We recruited Japanese patients who underwent PTA for CLI in Kansai Rosai Hospital, Hyogo, Japan, between 2003 and 2009.

All patients with chronic ischemic rest pain and/or foot ulcer or gangrene were evaluated for limb ischemia by angiography. The diagnosis and management of CLI were compliant with the Transatlantic Inter-Society Consensus (TASC) ([@B10]) or its revised consensus, TASC II ([@B1]). Once they were diagnosed as having CLI, we utilized PTA as the first-choice procedure for revascularization, within the recommendations in TASC II. The indication of PTA was judged by consensus among vascular specialists, including vascular surgeons. PTA was not considered to be feasible when lesions were heavily calcified and/or with diffuse occlusions, whereas poor-risk patients, having relative contraindications for bypass surgery, those with advanced age, expected high mortality under general anesthesia, and morbidity setting, for instance, would not necessarily be contraindications for PTA.

Major amputation, namely, above-the-ankle amputation, was indicated when revascularization failed to relieve patients from rest pain or control their foot lesions. The indication for amputation was judged by consensus among plastic surgeons as well as vascular specialists. Insufficient blood flow even after revascularization and uncontrollable limb infection were considered to be indications for amputation.

In the current study, we analyzed all of the recruited patients as well as those with diabetes. The outcome measures were limb loss by major amputation and mortality. The preoperative variables considered in the analyses were sex, age, activities of daily living (ADLs), Fontaine stage, the presence of infection, diabetic condition, hypertension, dyslipidemia, smoking, receiving regular hemodialysis, and serum albumin level as a nutritional marker. Diabetic condition was determined as the presence of diabetes in the whole population and as a glycemic control in the diabetic population. The diagnosis of diabetes was based on World Health Organization criteria, whereas glycemic control of diabetic patients was evaluated by A1C. Hypertension was diagnosed as systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg or having been treated for hypertension. Dyslipidemia was defined as serum LDL cholesterol ≥100 mg/dl or HDL cholesterol \<40 mg/dl or triglycerides ≥150 mg/dl or having been treated for dyslipidemia. Partial or total dependence in transferring (requiring some help in moving in and out of bed/chair or a complete transfer) were regarded as impaired ADLs.

Statistical analysis
--------------------

Data are given as means and SDs for continuous variables or as percentages for dichotomous variables. Limb salvage and survival were plotted using the Kaplan-Meier method, and, if necessary, the differences between the two groups were assessed by a log-rank test. Cox proportional hazards regression model was used to determine the unadjusted association of each variable with the outcome. The statistically significant variables in the univariate analyses, as well as sex and age, were entered into multivariate models to reveal the independent impact on the outcome. Hazard ratios (HRs) and 95% CIs are reported. *P* \< 0.05 was considered significant. Statistical analyses were performed using SPSS version 15.0J (SPSS, Chicago, IL).

RESULTS
=======

A total of 278 CLI patients undergoing primary PTA procedures were recruited; aorto-iliac lesions were revascularized in 23% of the population, femoro-popliteal in 63%, and infrapopliteal in 68%. Baseline characteristics are shown in [Table 1](#T1){ref-type="table"}. The prevalence of diabetes was 71%, and their mean A1C level was 7.0%. Diabetic patients had a significantly higher prevalence of Fontaine stage IV and hemodialysis than those without diabetes (*P* = 0.006 and *P* = 0.001, respectively).

###### 

Baseline characteristics of the study population

                           The whole population   Diabetic subjects   Nondiabetic subjects   *P* value (diabetes vs. nondiabetes)
  ------------------------ ---------------------- ------------------- ---------------------- --------------------------------------
  *n*                      278                    197                 81                     
  Male                     183 (66)               133 (68)            50 (62)                0.404
  Age (years)              71.4 ± 10.5            70.6 ± 9.7          73.3 ± 12.2            0.047
  Impaired ADLs            106 (38)               73 (37)             33 (41)                0.589
  Fontaine stage IV        228 (82)               170 (86)            58 (72)                0.006
  Diabetes                 197 (71)               ---                 ---                    ---
  Hypertension             232 (83)               165 (84)            67 (83)                0.860
  Dyslipidemia             214 (77)               158 (80)            56 (69)                0.059
  Smoking                  190 (68)               129 (65)            61 (75)                0.120
  Receiving hemodialysis   126 (45)               102 (52)            24 (30)                0.001
  Albumin (g/dl)           3.4 ± 0.6              3.5 ± 0.6           3.4 ± 0.7              0.279
  A1C (%)                  ---                    7.0 ± 1.4           ---                    ---

Data are *n* (%) or means ± SD. Differences between continuous variables of diabetic and nondiabetic groups were evaluated by unpaired *t* tests, whereas dichotomous variables between the two groups were compared by Fisher exact tests.

Follow-up period was 90 ± 72 weeks (1.7 ± 1.4 years), and 48 patients underwent major amputations and 89 died. [Figure 1](#F1){ref-type="fig"} shows the cause of death and Kaplan-Meier estimates of major amputation and mortality. The leading cause of death was cardiac and vascular disease (*n* = 40); followed by infection (*n* = 31), including pneumonia (*n* = 16), sepsis secondary to infective gangrene of the foot (*n* = 8), bed sore infection (*n* = 1), and catheter-related infection (*n* = 1); and unspecified causes (*n* = 5). Diabetic patients had a higher rate of major amputation compared with nondiabetic patients (*P* = 0.008, log-rank test), whereas they had a similar life prognosis (*P* = 0.717).

![Prognosis of CLI patients undergoing PTA. The cause of death in the whole population (*A*) and in the population with diabetes (*B*). Kaplan-Meier estimates of major amputation (*C* and *D*) and survival (*E* and *F*) in the whole population. The prognosis was compared between diabetic patients (solid line) and nondiabetic patients (dotted line) in *D* (*P* = 0.008, log-rank test) and *F* (*P* = 0.717, log-rank test). CV, cardiac and vascular disease; MN, malignant neoplasm; DM, diabetes.](zdc0121086140001){#F1}

Prognostic factors in the whole population
------------------------------------------

[Table 2](#T2){ref-type="table"} shows the influence of preoperative variables on the prognosis in the whole population. The presence of diabetes was independently associated with major amputation, and the adjusted HR was 3.101 (95% CI 1.262--7.621) (*P* = 0.014). The variable had, however, no statistically significant influence on mortality. Rather, mortality was associated with age, impaired ADLs, hemodialysis, and serum albumin level; the adjusted HRs were 1.036 (1.010--1.063) in the 1-year increment (*P* = 0.007) and 2.302 (1.407--3.605) (*P* \< 0.001), 2.699 (1.682--4.332) (*P* \< 0.001), and 1.788 (1.150--2.782) in the 1-g/dl decrement (*P* = 0.010), respectively.

###### 

Association of preoperative variables with the prognosis of CLI patients undergoing PTA

  Outcome measures                        Univariate model                                        Multivariate model
  --------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Major amputation                                                                                
      Preoperative variables                                                                      
          Male                            1.030 (0.565--1.877)                                    0.746 (0.400--1.391)
          Age (in 1-year increments)      0.983 (0.958--1.009)                                    0.989 (0.959--1.020)
          Impaired ADLs                   2.102 (1.191--3.711)[\*](#TF2-1){ref-type="table-fn"}   1.777 (0.972--3.250)
          Fontaine stage IV               6.607 (1.603--27.24)[†](#TF2-2){ref-type="table-fn"}    4.326 (1.028--18.20)[\*](#TF2-1){ref-type="table-fn"}
          Infection                       2.663 (1.480--4.791)[†](#TF2-2){ref-type="table-fn"}    2.298 (1.177--4.486)[\*](#TF2-1){ref-type="table-fn"}
          Diabetes                        2.992 (1.272--7.039)[\*](#TF2-1){ref-type="table-fn"}   3.101 (1.262--7.621)[\*](#TF2-1){ref-type="table-fn"}
          Hypertension                    0.561 (0.292--1.078)                                    ---
          Dyslipidemia                    0.678 (0.364--1.265)                                    ---
          Smoking                         0.995 (0.540--1.832)                                    ---
          Receiving hemodialysis          2.778 (1.508--5.117)[†](#TF2-2){ref-type="table-fn"}    2.875 (1.481--5.582)[\*](#TF2-1){ref-type="table-fn"}
          Albumin (in 1-g/dl increase)    0.577 (0.365--0.914)[\*](#TF2-1){ref-type="table-fn"}   0.659 (0.361--1.202)
  Mortality                                                                                       
      Preoperative variables                                                                      
          Male                            1.567 (0.974--2.521)                                    1.481 (0.902--2.429)
          Age (in 1-year increments)      1.027 (1.005--1.049)[\*](#TF2-1){ref-type="table-fn"}   1.036 (1.010--1.063)[†](#TF2-2){ref-type="table-fn"}
          Impaired ADLs                   3.272 (2.135--5.013)[†](#TF2-2){ref-type="table-fn"}    2.302 (1.470--3.605)[†](#TF2-2){ref-type="table-fn"}
          Fontaine stage IV               1.772 (0.975--3.221)                                    ---
          Infection                       2.106 (1.365--3.250)[†](#TF2-2){ref-type="table-fn"}    1.206 (0.710--2.050)
          Diabetes                        1.090 (0.683--1.742)                                    ---
          Hypertension                    0.736 (0.447--1.211)                                    ---
          Dyslipidemia                    0.847 (0.519--1.383)                                    ---
          Smoking                         1.100 (0.700--1.729)                                    ---
          Receiving hemodialysis          2.290 (1.486--3.527)[†](#TF2-2){ref-type="table-fn"}    2.699 (1.682--4.332)[†](#TF2-2){ref-type="table-fn"}
          Albuimn (in 1-g/dl increment)   0.496 (0.357--0.688)[†](#TF2-2){ref-type="table-fn"}    0.559 (0.359--0.870)[†](#TF2-2){ref-type="table-fn"}

Data are HR (95% CI).

\**P* value \<0.05;

†*P* value \<0.01.

Prognostic factors in the diabetic population
---------------------------------------------

We also performed analyses with a focus on the patients with diabetes ([Table 3](#T3){ref-type="table"}). Here again, mortality was associated with age, impaired ADLs, hemodialysis, and serum albumin level. No significant association was found between mortality and A1C level. A1C level was, however, independently associated with major amputation, whose adjusted HR was 1.349 (95% CI 1.103--1.650) in the 1% increment (*P* = 0.004). Its association was still significant in the multivariate models in which every other peripheral vascular factor available in our dataset was substituted for Fontaine stage IV (online appendix Table A, available at <http://care.diabetesjournals.org/cgi/content/full/dc10-0939/DC1>).

###### 

Association of preoperative variables for the prognosis with CLI patients with diabetes undergoing PTA

  Outcome measures                        Univariate model                                        Multivariate model
  --------------------------------------- ------------------------------------------------------- ------------------------------------------------------
  Major amputation                                                                                
      Preoperative variables                                                                      
          Male                            1.242 (0.636--2.427)                                    1.042 (0.515--2.105)
          Age (in 1-year increments)      0.987 (0.957--1.019)                                    1.010 (0.975--1.046)
          Impaired ADL                    1.763 (0.957--3.247)                                    ---
          Fontaine stage IV               4.299 (1.038--17.81)[\*](#TF3-1){ref-type="table-fn"}   3.987 (0.942--16.87)
          Infection                       2.158 (1.133--4.110)[\*](#TF3-1){ref-type="table-fn"}   2.883 (1.450--5.731)[†](#TF3-2){ref-type="table-fn"}
          Hypertension                    0.800 (0.370--1.727)                                    ---
          Dyslipidemia                    0.638 (0.320--1.270)                                    ---
          Smoking                         1.141 (0.593--2.195)                                    ---
          A1C (in 1% increment)           1.218 (1.006--1.475)[\*](#TF3-1){ref-type="table-fn"}   1.349 (1.103--1.650)[†](#TF3-2){ref-type="table-fn"}
          Receiving hemodialysis          2.434 (1.246--4.757)[†](#TF3-2){ref-type="table-fn"}    4.176 (1.976--8.825)[†](#TF3-2){ref-type="table-fn"}
          Albumin (in 1-g/dl increment)   0.624 (0.366--1.064)                                    ---
  Mortality                                                                                       
      Preoperative variables                                                                      
          Male                            1.328 (0.769--2.293)                                    1.376 (0.784--2.414)
          Age (in 1-year increment)       1.032 (1.005--1.061)[\*](#TF3-1){ref-type="table-fn"}   1.045 (1.012--1.080)[†](#TF3-2){ref-type="table-fn"}
          Impaired ADL                    3.124 (1.890--5.163)[†](#TF3-2){ref-type="table-fn"}    2.514 (1.506--4.197)[†](#TF3-2){ref-type="table-fn"}
          Fontaine stage IV               2.120 (0.952--4.722)                                    ---
          Infection                       1.618 (0.960--2.727)                                    ---
          Hypertension                    0.874 (0.475--1.607)                                    ---
          Dyslipidemia                    0.975 (0.520--1.828)                                    ---
          Smoking                         1.093 (0.650--1.839)                                    ---
          A1C (in 1% increment)           0.897 (0.742--1.084)                                    ---
          Receiving hemodialysis          2.082 (1.242--3.490)[†](#TF3-2){ref-type="table-fn"}    3.046 (1.720--5.395)[†](#TF3-2){ref-type="table-fn"}
          Albumin (in 1-g/dl increment)   0.498 (0.330--0.751)[†](#TF3-2){ref-type="table-fn"}    0.423 (0.260--0.688)[†](#TF3-2){ref-type="table-fn"}

Data are HR (95% CI).

\**P* value \<0.05;

†*P* value \<0.01.

Next, we divided the A1C dataset into quartiles to analyze the relationship between the increment of A1C level and the risk for major amputation in the diabetic patients. A1C ≤5.9% was categorized into the first quartile (Q1), 6.0--6.7% into the second quartile (Q2), 6.8--7.6% into the third quartile (Q3), and ≥7.7% into the fourth quartile (Q4). In a stepwise multivariate model, the categorized A1C level was independently associated with major amputation, with adjustment for Fontaine stage IV, hemodialysis, and infection. The adjusted HRs of Q2, Q3, and Q4 relative to Q1 were 2.030 (95% CI 0.657--6.266) (*P* = 0.218), 3.398 (1.227--9.412) (*P* = 0.019), and 3.983 (1.398--11.35) (*P* = 0.010), respectively.

We further analyzed the influence of the presence of diabetes on major amputation according to their A1C level; each A1C quartile of the diabetic group, defined above, was compared with the nondiabetic group in a stepwise multivariate model. As shown in [Fig. 2](#F2){ref-type="fig"}*A*, the two higher A1C quartiles of the diabetic group (that is, the diabetic group with A1C ≥6.8%) had a significantly higher risk than the nondiabetic group, whereas the two lower A1C quartiles (that is, A1C \<6.8%) did not. Based on these findings, we reanalyzed with substitution of diabetes with A1C ≥6.8% for the presence of diabetes in the original multivariate model shown in [Table 2](#T2){ref-type="table"}. The result was that diabetes with A1C ≥6.8%, infection, and hemodialysis were significantly associated with major amputation; their adjusted HRs were 2.907 (95% CI 1.606--5.264) (*P* \< 0.001), 2.375 (1.198--4.711) (*P* = 0.014), and 3.530 (1.772--7.029) (*P* \< 0.001), respectively (online appendix Table B). Note that these three variables were independent of one another and therefore were expected to have additive influences on major amputation. In fact, a Kaplan-Meier model showed that those with the accumulation of these prognostic factors had an increased risk of major amputation ([Fig. 2](#F2){ref-type="fig"}*B*). When they had all of these three risk factors, their prognosis was extremely poor. Their estimated median time to limb loss was only 23 weeks, which would be rarely different from natural course of nonrevascularized CLI patients ([@B1]).

![The association of poor glycemic control and other variables with major amputation. *A*: The adjusted HRs for major amputation according to glycemic control. Data are the adjusted HRs and 95% CIs of each A1C quartile of the diabetic group relative to the nondiabetic group in the stepwise multivariate model. They were adjusted for impaired activity of daily living, Fontaine stage IV, infection, and receiving hemodialysis. The quartiles of A1C were as follows: Q1: ≤5.9%, Q2: 6.0--6.7%, Q3: 6.8--7.6%, and Q4: ≥7.7%. *B*: Kaplan-Meier estimates of major amputation according to the number of risk factors (*P* \< 0.001, log-rank test). Risk factors considered here are the following three variables: diabetes with A1C ≥6.8%, the presence of infection, and receiving hemodialysis, all of which had independent associations in the stepwise multivariate Cox proportional hazards regression model. DM, diabetes.](zdc0121086140002){#F2}

CONCLUSIONS
===========

As is mentioned in the TASC II ([@B1]), a primary outcome in CLI patients would be amputation-free survival, although it remains unclear so far, especially in the population undergoing PTA, which preoperative variables are associated with their prognosis and whether morality and limb loss have the same predictive factors.

In the current study, A1C level was significantly associated with major amputation in patients with diabetes. It is possible that infection might lead to poor glycemic control. The multivariate model, however, showed that A1C level had a significant association with major amputation independently of infection.

The current study also confirmed that the presence of diabetes was significantly associated with major amputation in the whole population and that its significant association was dependent on the glycemic control. Some investigators already reported the association between diabetes and limb loss ([@B11],[@B12]), but they did not take glycemic control into consideration. We did investigate risk of major amputation according to glycemic control. Interestingly, when compared with nondiabetes, diabetes A1C ≥6.8%, but not A1C \<6.8%, was significantly associated with major amputation. This finding suggests that the increased risk of major amputation for diabetic patients is mainly attributed to their poor glycemic control. The mechanism of association between poor glycemic control and poor limb prognosis remains unclear. It is well known, however, that poor glycemic control is associated with decreased immune response and delayed wound healing, as well as the progression of microangiopathy including neuropathy, all of which play an important part of foot lesions ([@B13][@B14]--[@B15]); the existence of poor glycemic control might reflect these underlying conditions.

In discussion of limb prognoses of PAD patients, the severity of PAD itself should be taken into consideration. There exist several ways of assessing preoperatively their peripheral arterial severity. In the current study, we adopted Fontaine stages, a widely used clinical classification, and found that it was not significantly associated with limb salvage in a multivariate model, as was poor glycemic control. To examine this paradoxical result, we further analyzed with two other preoperative peripheral arterial factors available in our dataset, namely ankle-brachial index, which is physiological, and runoff below the ankle before PTA, which is anatomical (or imaging). Yet, the results were similar; no preoperative peripheral arterial factors had independent associations with limb loss (online appendix Table A). In contrast, a postoperative variable, the runoff below the ankle after PTA, was significantly associated with major amputation. One interpretation of these findings is that the limb prognosis depends on the peripheral blood flow after, rather than before, revascularization. Successful revascularizations would improve peripheral blood flow and could lead to avoidance of limb loss, even if the preoperative peripheral flow is severely impaired. The severity of preoperative peripheral flow would not always mean the similar severity of postoperative peripheral flow. Given that peripheral blood flow can be changed by revascularization procedures, it is not surprising that limb prognosis after PTA is associated with postoperative, rather than preoperative, peripheral arterial factors.

We also surveyed the influence of preoperative variables on survival, which confirmed that diabetes failed to have a significant association with morality. Some recent trials ([@B11],[@B12],[@B16][@B17]--[@B18]) likely supported the absence of this association. Yet, most studies surveyed CLI patients undergoing PTA together with those undergoing bypass surgery and/or nonrevascularized patients, whereas we limited our study population to those undergoing PTA. In addition, we revealed that A1C level in diabetic patients had no significant association with mortality. The prognostic factors for mortality were, rather, age, impaired ADLs, hemodialysis, and serum albumin level. These significant associations were affirmed even with additional adjustment for cardiac function or ejection fraction evaluated with echocardiography (online appendix Table C). Previous reports ([@B9],[@B18],[@B19]) investigated some of these prognostic variables, but they did not mention nutritional status in the population. As is well known, malnutrition affects life prognosis in various clinical situations ([@B20],[@B21]). We adopted serum albumin level as a nutritional marker in the current study because of its great advantages in ease and cost and its wide use in clinical practice. It is possible that serum albumin level is affected by clinical factors other than malnutrition. But we confirmed the relationship between malnutrition and mortality by the analyses with other nutrition-related markers, such as lymphocyte count and serum cholinesterase level (online appendix Table D).

In conclusion, we investigated the association of preoperative variables with the prognosis of CLI patients undergoing PTA, which suggests that prognostic indicators are somewhat different between survival and limb salvage. Diabetes and poor glycemic control, for instance, was significantly associated with limb loss but not mortality. Diabetes with poor glycemic control, infection, and hemodialysis was independently associated with limb loss, and the accumulation of these prognostic factors increased the amputation risk. Especially, those with all of the three risk factors had such poor limb prognosis that they might fail to receive a prognostic benefit of PTA. It is possible, however, that correction of poor glycemic control by adequate interventions leads to prognostic improvement. A further prospective investigation is required to determine whether the intervention on glycemic control subsequently improves their prognosis.
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